The decision could help save the NHS millions of pounds due to Metalyse costing less than the current standard for treating this type of stroke, Actilyse (alteplase), which is also sold by Boehringer in the UK.
Strokes are estimated to be responsible for around 100,000 hospital admissions in England every year.
Representing around 85% of all stroke cases in the UK, AIS occurs when there is a blockage in a blood vessel, resulting in a restricted blood supply to the brain…
